Method of treating chronic lymphatic leukaemia and/or systemic lupus erythematosus
AssigneesUniversite De Bretagne Occidentale (U.B.O.), Inserm, Centre Hospitalier RéGional Et Universitaire De Brest
InventorsYves RENAUDINEAU, Olivier MIGNEN, Miguel BURGOS, Jacques Olivier PERS, Tinhinane FALI
Life of this patent
Estimating the term…
Abstract
A method of treating a patient suffering from chronic lymphatic leukaemia (CLL) and/or systemic lupus erythematosus (SLE) is described. The method includes administering to the patient in need thereof an effective amount of a substance interacting with the fraction of the STIM1 protein localized to the plasma membrane of the cells.
Claims17
A method of treating a patient suffering from chronic lymphatic leukaemia (CLL) and/or systemic lupus erythematosus (SLE) comprising administering to the patient in need thereof an effective amount of a substance interacting with the fraction of the STIM1 protein localized to the plasma membrane of the cells.
Use of the isolated fraction of the STIM1 protein localized to the plasma membrane of the cells in a method for screening in vitro candidate molecules for treating chronic lymphatic leukaemia and/or systemic lupus erythematosus, wherein the cells are isolated entire cells.
A method of identifying, in vitro, substances useful for treating chronic lymphatic leukemia and/or systemic lupus erythematosus, comprising the steps of:
- (a) providing a sample containing isolated entire cells expressing on their surface a fraction of STIM1 protein localized to the plasma membrane on the cells,
- (b) screening candidate molecules by interacting the cells with candidate molecules,
- (c) selecting candidate molecules that binds to the fraction of the STIM1 protein localized to the plasma membrane of the cells without penetrating the cells,
- thereby identifying substances useful for treating chronic lymphatic leukemia and/or systemic lupus erythematosus.
Dependencies are inferred from the claim text.